- Home
- DPRO vs EVAX Comparison
DPRO vs EVAX Comparison
Compare DPRO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPRO
- EVAX
- Stock Information
- Founded
- DPRO 1998
- EVAX 2008
- Country
- DPRO Canada
- EVAX Denmark
- Employees
- DPRO N/A
- EVAX N/A
- Industry
- DPRO Aerospace
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DPRO Industrials
- EVAX Health Care
- Exchange
- DPRO Nasdaq
- EVAX Nasdaq
- Market Cap
- DPRO 17.3M
- EVAX 16.3M
- IPO Year
- DPRO N/A
- EVAX 2021
- Fundamental
- Price
- DPRO $2.80
- EVAX $2.53
- Analyst Decision
- DPRO Strong Buy
- EVAX Strong Buy
- Analyst Count
- DPRO 2
- EVAX 3
- Target Price
- DPRO $7.00
- EVAX $33.33
- AVG Volume (30 Days)
- DPRO 130.9K
- EVAX 6.8M
- Earning Date
- DPRO 03-26-2025
- EVAX 03-26-2025
- Dividend Yield
- DPRO N/A
- EVAX N/A
- EPS Growth
- DPRO N/A
- EVAX N/A
- EPS
- DPRO N/A
- EVAX N/A
- Revenue
- DPRO $4,340,793.00
- EVAX $3,295,000.00
- Revenue This Year
- DPRO $14.33
- EVAX $9,039.73
- Revenue Next Year
- DPRO $115.93
- EVAX $1.47
- P/E Ratio
- DPRO N/A
- EVAX N/A
- Revenue Growth
- DPRO N/A
- EVAX N/A
- 52 Week Low
- DPRO $1.55
- EVAX $2.22
- 52 Week High
- DPRO $9.13
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- DPRO 37.04
- EVAX 40.91
- Support Level
- DPRO $3.09
- EVAX $2.43
- Resistance Level
- DPRO $3.34
- EVAX $2.80
- Average True Range (ATR)
- DPRO 0.26
- EVAX 0.31
- MACD
- DPRO -0.02
- EVAX 0.07
- Stochastic Oscillator
- DPRO 2.80
- EVAX 16.94
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.